Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Kronos Bio Inc Market Cap
Based on ratings from 0 stock analysts, the Kronos Bio Inc stock price is expected to increase by 339.36% in 12 months. This is calculated by using the average 12-month stock price forecast for Kronos Bio Inc. The lowest target is $2.25 and the highest is $6. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assignedKRON 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Kronos Bio Inc to sell. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on KRON. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of KRON.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Robert Burns HC Wainwright & Co. | Buy | $2.25 | Reiterates | Aug 19, 2024 |
| Robert Burns HC Wainwright & Co. | Buy | $2.25 | Reiterates | Aug 1, 2024 |
| Robert Burns HC Wainwright & Co. | Buy | $2.25 | Maintains | May 3, 2024 |
| Edward Tenthoff Piper Sandler | Overweight | $6 | Maintains | Dec 19, 2023 |
| Robert Burns HC Wainwright & Co. | Buy | $2.5 | Maintains | Dec 19, 2023 |
| Robert Burns HC Wainwright & Co. | Buy | $9 | Reiterates | Nov 27, 2023 |
| Robert Burns HC Wainwright & Co. | Buy | $9 | Maintains | Aug 21, 2023 |
| Robert Burns HC Wainwright & Co. | Buy | $10 | Reiterates | Apr 17, 2023 |
| Robert Burns HC Wainwright & Co. | Buy | $10 | Maintains | Nov 18, 2022 |
| Salveen Richter Goldman Sachs | Buy | $14 | Maintains | Nov 10, 2022 |
| Edward Tenthoff Piper Sandler | Overweight | $7 | Maintains | Nov 9, 2022 |
| Zhiqiang Shu Berenberg | Buy | $12 | Initiates | Sep 14, 2022 |
| Salveen Richter Goldman Sachs | Buy | $23 | Maintains | May 24, 2022 |
| Edward Tenthoff Piper Sandler | Overweight | $13 | Maintains | May 23, 2022 |
| Edward Tenthoff Piper Sandler | Overweight | $30 | Maintains | Feb 28, 2022 |
| Robert Burns HC Wainwright & Co. | Buy | $36 | Maintains | Nov 10, 2021 |
HC Wainwright & Co. | Buy | Initiates | Jun 24, 2021 | |
Piper Sandler | Overweight | Initiates | Nov 3, 2020 | |
Goldman Sachs | Buy | Initiates | Nov 3, 2020 | |
Cowen & Co. | Outperform | Initiates | Nov 3, 2020 |
When did it IPO
2020
Staff Count
58
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Norbert W. Bischofberger Ph.D.
Market Cap
$60.0M
In 2023, KRON generated $6.3M in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that KRON's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Fri, 27 Oct 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Brian Van Tine, M.D., of Washington University School of Medicine to share datau00a0 from the ongoing Phase 1/2 study at leading international sarcoma meeting
Fri, 13 Oct 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Demonstrated on-mechanism, single agent anti-tumor activity in heavily pre-treated patients with transcriptionally addicted solid tumors
Wed, 04 Oct 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Management to host conference call and webcast on October 13 at 4:30 PM ET with key opinion leader and KB-0742 trial investigator, Miguel Villalona-Calero, M.D., of City of Hope Management to host conference call and webcast on October 13 at 4:30 PM ET with key opinion leader and KB-0742 trial investigator, Miguel Villalona-Calero, M.D., of City of Hope
Thu, 17 Aug 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - SAN MATEO, Calif. and CAMBRIDGE, Mass., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, announced that its Chief Financial Officer and Head of Corporate Development, Yasir Al-Wakeel, BM BCh, will resign from his position to pursue a new professional opportunity as the chief executive officer of a private biotechnology company. The Company has initiated a search to identify a suitable replacement for Dr. Al-Wakeel, who will remain with Kronos Bio until September 15, 2023 to ensure business continuity.
Tue, 08 Aug 2023
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Kronos Bio, Inc. (KRON) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.59 per share a year ago.
Tue, 08 Aug 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Data from the Phase 1 dose escalation portion of the Phase 1/2 KB-0742 study will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in October 2023
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
